RELATIVITY-123 MSS CRC unlikely to reach primary endpoint and will be discontinued
Other trials evaluating fixed-dose combinations of nivolumab and leratorimab as treatments for other tumor types will continue. The phase 3 RELATIVITY-123 trial (NCT05328908) tested nivolumab (Opdivo) and relatlimab (Opdurag) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who had disease progression after 1 to 4 days. ) is evaluating the effectiveness of combination […]
Cureus oro-anal transit time and colonic manometry: Predictability and outcomes in children with functional constipation Purpose: The primary objective of this study was to measure oro-anal transit time using SITZMARKS® (Konsyl…1 month ago) The objective was to evaluate the correlation between time (OTT).
Cureus oro-anal transit time and colonic manometry: Predictability and outcomes in children with functional constipation Purpose: The primary objective of this study was to measure oro-anal transit time using SITZMARKS® (Konsyl…1 month ago) The objective was to evaluate the correlation between time (OTT).
A rare case of recurrent cystitis in a primary care setting.
specialty Please chooseI’m not a medical professional.Allergy and immunologyanatomyanesthesiologyCardiac, thoracic, and vascular surgerycardiologyCritical caredentalDermatologyDiabetes and endocrinologyemergency medical careepidemiology and public healthRegular medicineForensic medicineDepartment of GastroenterologyGeneral medical treatmentgeneticsgeriatricsmedical policyHematologyHIV/AIDShospital-based medical careI’m not a medical professional.InfectionIntegrative medicine/complementary medicineInternal medicineInternal medicine/pediatricsMedical education and simulationmedical physicsmedical studentnephrologyneurosurgeryneurologynuclear medicinenutritionObstetrician and gynecologistoccupational healthoncologyophthalmologyoptometryOral medicineorthopedic surgeryosteopathic medicineOtorhinolaryngologypain managementpalliative carePathologyPediatricspediatric surgeryPhysical therapy and […]
Motixafortide shows efficacy as primary treatment for pancreatic cancer in phase 2 trial
Pancreas image | Image credit: © Лилия Захарчук – Stock.adobe.com Motixafortide, a CXC4 inhibitor, when combined with the PD-1 inhibitor cemiplimab and the standard of care (SoC) chemotherapy treatment gemcitabine and nab-paclitaxel (MCGN) Phase 2 Data from the CheMo4METPANC trial (NCT04543071) showed some positive results against (mPDAC). This data, presented as an abstract as part […]